^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BCY6033

    i
    Other names: BCY6033
    Company:
    Bicycle Therap
    Drug class:
    Microtubule inhibitor, EphA2 receptor antagonist
    Related drugs:
    2years
    Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts (AACR 2022)
    Here we report on EphA2 expression in well characterized and clinically annotated patient derived xenografts (PDX) of NSCLC including EGFR mutant NSCLC derived either from erlotinib or osimertinib resistant patients. BCY6033 is a potentially promising drug effective against EphA2 expressing PDX models. Future studies and clinical trials will seek to determine the efficacy of BT5528 in EphA2 expressing tumors.
    Clinical
    |
    EPHA2 (EPH receptor A2)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • erlotinib • BCY6033 • BT5528